Alefacept

Generic Name: Alefacept

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 222535-22-0

Unique Ingredient Identifier: ELK3V90G6C

Background: Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.

Indication: As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis

Phase 2

Completed

Conditions: Psoriasis
Palmoplantaris Pustulosis
Pustular Psoriasis of Palms and Soles
Pustulosis Palmaris et Plantaris
Pustulosis of Palms and Soles

First Posted Date: 2006-03-10

Last Posted Date: 2006-11-23

Lead Sponsor: The Guenther Dermatology Research Centre

Target Recruit Count: 15

Registration Number: NCT00301002

Locations: 🇨🇦
The Guenther Dermatology Research Centre, London, Ontario, Canada

Safety and Tolerability of Repeat Courses of IM Alefacept

Phase 3

Completed

Conditions: Chronic Plaque Psoriasis

First Posted Date: 2005-10-06

Last Posted Date: 2023-08-23

Lead Sponsor: Biogen

Target Recruit Count: 400

Registration Number: NCT00233662

Locations: 🇨🇦
Dermatrials Research, Hamilton, Ontario, Canada
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇫🇷
Hopital L'Archet II, Nice, France

and more 43 locations

Community Based Trial for AMEVIVE®

Phase 4

Completed

Conditions: Moderate to Severe Chronic Plaque Psoriasis

Interventions: Drug: Alefacept

First Posted Date: 2005-09-15

Last Posted Date: 2014-09-08

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 114

Registration Number: NCT00168753

Locations: 🇺🇸
Michael Scannon, Tampa, Florida, United States
🇺🇸
Calumet Dermatology Associates, Calumet City, Illinois, United States
🇺🇸
Skin and Cancer Associates, Tamarac, Florida, United States

and more 33 locations

Alefacept in Patients With Severe Scalp Alopecia Areata

Not Applicable

Completed

Conditions: Alopecia Areata

Interventions: Drug: Alefacept

First Posted Date: 2005-09-14

Last Posted Date: 2019-05-22

Lead Sponsor: University of Minnesota

Target Recruit Count: 45

Registration Number: NCT00167102

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy